Drug
Tasimelteon clinical trials
Also written VEC-162, BMS-214778 and Hetlioz.
- studies test it
- 26
- open now
- 2
- in phase 3
- 12
- first study started
- 2004
Keep track of what changes. Save the tasimelteon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 4
- Phase 3
- 12
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 1
Vanda Pharmaceuticals (25) · Brigham and Women's Hospital (1)
Often tested with
Tested in the same studies.
Rosiglitazone (1) · Midazolam (1) · Ethanol (1) · Rifampin (1) · Ketoconazole (1) · Fluvoxamine (1)
Studies
Open first, then newest update. How each study uses tasimelteon is read from its arms, and is right about nine times in ten.
Testing it · 26
- Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaRecruitingPhase 3Vanda PharmaceuticalsNCT06953869Written as Tasimelteon Oral Suspension
- Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantRecruitingPhase 3Vanda PharmaceuticalsNCT06701396Written as Tasimelteon
- Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)CompletedPhase 3Vanda PharmaceuticalsNCT04652882Written as Tasimelteon
- The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)TerminatedEarly Phase 1Brigham and Women's HospitalNCT05922995Written as Tasimelteon
- Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionActive, not recruitingPhase 3Vanda PharmaceuticalsNCT01218789Written as tasimelteon
- Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy SubjectsCompletedPhase 1Vanda PharmaceuticalsNCT06323655Written as Tasimelteon
- Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy VolunteersCompletedPhase 1Vanda PharmaceuticalsNCT05572281Written as Tasimelteon Oral Capsule
- Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCompletedPhase 1Vanda PharmaceuticalsNCT02776215Written as tasimelteon
- Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaCompletedPhase 3Vanda PharmaceuticalsNCT03373201Written as Tasimelteon
- Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSCompletedPhase 2/3Vanda PharmaceuticalsNCT02231008Written as tasimelteon
- A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag DisorderCompletedPhase 2Vanda PharmaceuticalsNCT03291041Written as Tasimelteon
- Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)CompletedPhase 4Vanda PharmaceuticalsNCT02130999Written as tasimelteon 20 mg capsule
- Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive DisorderCompletedPhase 2/3Vanda PharmaceuticalsNCT01428661Written as tasimelteon
- Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionCompletedPhase 3Vanda PharmaceuticalsNCT01429116Written as tasimelteon
- Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderCompletedPhase 3Vanda PharmaceuticalsNCT01163032Written as tasimelteon
- VEC-162 Study in Adult Patients With Primary InsomniaCompletedPhase 3Vanda PharmaceuticalsNCT00548340Written as VEC-162 20 mg
- VEC-162 Study in Healthy Adult Volunteers in a Model of InsomniaCompletedPhase 3Vanda PharmaceuticalsNCT00291187Written as 20 mg VEC-162
- Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake DisorderCompletedPhase 3Vanda PharmaceuticalsNCT01430754Written as tasimelteon
- Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult VolunteersCompletedPhase 2Vanda PharmaceuticalsNCT00490945Written as VEC-162
- A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy SubjectsCompletedPhase 1Vanda PharmaceuticalsNCT01402076Written as Tasimelteon
Codes
What other systems call tasimelteon · ClinicalTrials.gg INT004575
- MeSH (NLM) C478745tasimelteonOne source NLM
- UNII (FDA) SHS4PU80D9TASIMELTEONConfirmed FDA, NLM, Wikidata
- RxNorm 1490468Confirmed FDA, Wikidata
- Wikidata Q7687250tasimelteonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152515TasimelteonOne source FDA
- DrugBank DB09071One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C478745 | tasimelteon | One source NLM |
| UNII (FDA) | SHS4PU80D9 | TASIMELTEON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1490468 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7687250 | tasimelteon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152515 | Tasimelteon | One source FDA |
| DrugBank | DB09071 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.